BACKGROUND/ OBJECTIVES: Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by intravascular haemolysis with a negative direct antiglobulin test (DAT). Eculizumab is a humanized monoclonal antibody that inhibits complement component C5 and is approved for PNH treatment. Recent publications demonstrated that some patients with PNH develop a positive DAT during eculizumab treatment. These published clinical trials investigated a highly selected patient population. Therefore, it seems important to study this topic in a general PNH patient population with a longer follow-up. MATERIALS AND METHODS: We analysed haemolytic activity, RBC transfusion requirement, effect on DAT and ferritin levels in 41 patients with PNH before and during eculizumab therapy with a median follow-up of 24 months (range 1-63 months). RESULTS: During eculizumab therapy, median LDH decreased (1657-258 U/l; P < 0·0001), while median haemoglobin increased (9·2-10·3 g/dl). Eighteen of 32 pts (56%) who previously required regular transfusions became transfusion independent. DAT was positive for C3d in 72·4% of 21 eculizumab-treated pts with available DAT. Ferritin levels increased (69-348 ng/ml, P < 0·0001). This increase was more pronounced in pts with ongoing transfusion dependency during eculizumab therapy. CONCLUSION: Eculizumab therapy for PNH should be added to the list of possible causes for a positive DAT. Intravascular haemolysis was inhibited by eculizumab, but signs of extravascular haemolysis should be monitored. Because renal iron loss was stopped, eculizumab-treated pts can be prone to iron overload and therefore ferritin concentrations should be monitored closely.
BACKGROUND/ OBJECTIVES:Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by intravascular haemolysis with a negative direct antiglobulin test (DAT). Eculizumab is a humanized monoclonal antibody that inhibits complement component C5 and is approved for PNH treatment. Recent publications demonstrated that some patients with PNH develop a positive DAT during eculizumab treatment. These published clinical trials investigated a highly selected patient population. Therefore, it seems important to study this topic in a general PNH patient population with a longer follow-up. MATERIALS AND METHODS: We analysed haemolytic activity, RBC transfusion requirement, effect on DAT and ferritin levels in 41 patients with PNH before and during eculizumab therapy with a median follow-up of 24 months (range 1-63 months). RESULTS: During eculizumab therapy, median LDH decreased (1657-258 U/l; P < 0·0001), while median haemoglobin increased (9·2-10·3 g/dl). Eighteen of 32 pts (56%) who previously required regular transfusions became transfusion independent. DAT was positive for C3d in 72·4% of 21 eculizumab-treated pts with available DAT. Ferritin levels increased (69-348 ng/ml, P < 0·0001). This increase was more pronounced in pts with ongoing transfusion dependency during eculizumab therapy. CONCLUSION:Eculizumab therapy for PNH should be added to the list of possible causes for a positive DAT. Intravascular haemolysis was inhibited by eculizumab, but signs of extravascular haemolysis should be monitored. Because renal iron loss was stopped, eculizumab-treated pts can be prone to iron overload and therefore ferritin concentrations should be monitored closely.
Authors: Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen Journal: Haematologica Date: 2010-02-09 Impact factor: 9.941
Authors: Antonio M Risitano; Rosario Notaro; Ludovica Marando; Bianca Serio; Danilo Ranaldi; Elisa Seneca; Patrizia Ricci; Fiorella Alfinito; Andrea Camera; Giacomo Gianfaldoni; Angela Amendola; Carla Boschetti; Eros Di Bona; Giorgio Fratellanza; Filippo Barbano; Francesco Rodeghiero; Alberto Zanella; Anna Paola Iori; Carmine Selleri; Lucio Luzzatto; Bruno Rotoli Journal: Blood Date: 2009-01-29 Impact factor: 22.113
Authors: T Miyata; J Takeda; Y Iida; N Yamada; N Inoue; M Takahashi; K Maeda; T Kitani; T Kinoshita Journal: Science Date: 1993-02-26 Impact factor: 47.728
Authors: Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen Journal: Blood Date: 2007-11-30 Impact factor: 22.113
Authors: Markus J Harder; Nadine Kuhn; Hubert Schrezenmeier; Britta Höchsmann; Inge von Zabern; Christof Weinstock; Thomas Simmet; Daniel Ricklin; John D Lambris; Arne Skerra; Markus Anliker; Christoph Q Schmidt Journal: Blood Date: 2016-12-27 Impact factor: 22.113
Authors: Christoph Q Schmidt; Markus J Harder; Eva-Maria Nichols; Mario Hebecker; Markus Anliker; Britta Höchsmann; Thomas Simmet; Ádám I Csincsi; Barbara Uzonyi; Isabel Y Pappworth; Daniel Ricklin; John D Lambris; Hubert Schrezenmeier; Mihály Józsi; Kevin J Marchbank Journal: Immunobiology Date: 2016-01-06 Impact factor: 3.144
Authors: Cristina Muñoz-Linares; Emilio Ojeda; Rafael Forés; Miguel Pastrana; Martín Cabero; Daniel Morillo; Guiomar Bautista; Isolina Baños; Carmen Monteserín; Pilar Bravo; Esther Jaro; Teresa Cedena; Juan Luis Steegmann; Ana Villegas; José Rafael Cabrera Journal: Eur J Haematol Date: 2014-05-13 Impact factor: 2.997
Authors: Jin Y Chen; Neeti S Galwankar; Heather N Emch; Smrithi S Menon; Claudio Cortes; Joshua M Thurman; Samuel A Merrill; Robert A Brodsky; Viviana P Ferreira Journal: Front Immunol Date: 2020-07-22 Impact factor: 7.561